共 52 条
[1]
Nanni C., Rubello D., Fanti S., Et al., Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer, Biomed Pharmacother, 60, pp. 409-413, (2006)
[2]
Kyle R.A., Durie B.G., Rajkumar S.V., Et al., Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, Leukemia, 24, pp. 1121-1127, (2010)
[3]
Smith D., Yong K., Multiple myeloma, BMJ, 346, (2013)
[4]
Rajkumar S.V., Dimopoulos M.A., Palumbo A., Et al., International myeloma working group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, 15, pp. e538-e548, (2014)
[5]
Rajkumar S.V., Myeloma today: disease definitions and treatment advances, Am J Hematol, 91, pp. 90-100, (2016)
[6]
Pratt G., Bowcock S., Chantry A., Et al., Time to redefine myeloma, Br J Haematol, 171, pp. 1-10, (2015)
[7]
Dimopoulos M.A., Hillengass J., Usmani S., Et al., Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement, J Clin Oncol, 33, pp. 657-664, (2015)
[8]
Hillengass J., Landgren O., Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma, Leuk Lymphoma, 54, pp. 1355-1363, (2013)
[9]
Hillengass J., Fechtner K., Weber M.A., Et al., Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma, J Clin Oncol, 28, pp. 1606-1610, (2010)
[10]
Padhani A.R., Khan A.A., Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy, Target Oncol, 5, pp. 39-52, (2010)

